A Novel Agent with Histone Deacetylase Inhibitory Activity Attenuates Neointimal Hyperplasia
M Rahmatzadeh, HB Liu, SM Krishna, TA Gaspari, I Welungoda, RE Widdop, AE Dear
CARDIOVASCULAR DRUGS AND THERAPY | SPRINGER | Published : 2014
PURPOSE: Neointimal hyperplasia (NIH), a pathophysiological event identified in bypass graft and stent re-stenosis, is characterised by aberrant vascular smooth muscle cell (VSMC) migration and proliferation. Recent evidence identifies histone deacetylase modulation as a regulator of VSMC proliferation and migration and a potential therapeutic target in the treatment of NIH. The purpose of our study was to determine the in vitro and in vivo potential of a novel agent, MCT-3, to modulate VSMC migration, proliferation and NIH. METHODS: In vitro VSMC studies utilized reverse transcriptase and real time Q-PCR gene expression analysis, western blot, elisa assay and cellular proliferation and migr..View full abstract
This research was supported in-part by the Monash University Strategic Grant Scheme.